erlotinib hydrochloride has been researched along with staurosporine in 4 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (staurosporine) | Trials (staurosporine) | Recent Studies (post-2010) (staurosporine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 6,272 | 58 | 976 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | staurosporine (IC50) |
|---|---|---|---|
| Chain A, Ribosomal protein S6 kinase alpha-1 | Homo sapiens (human) | 0.0003 | |
| Chain X, Tyrosine-protein kinase Lyn | Homo sapiens (human) | 0.0013 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Freidlin, B; Korn, EL; McShane, LM | 1 |
| Chan, E; Heffron, TP; La, H; Lee, HJ; Malek, S; Merchant, M; Pirazzoli, V; Politi, K; Schaefer, G; Settleman, J; Shao, L; Sideris, S; Ubhayakar, S; Yauch, RL; Ye, X | 1 |
| Bai, Y; Bennett, K; Colinge, J; Eschrich, S; Fang, B; Grebien, F; Haura, EB; Kim, JY; Koomen, J; Li, J; Okamoto, I; Qian, X; Rawal, B; Rix, U; Schell, M; Song, L; Stukalov, A; Superti-Furga, G; Winter, G; Yoshida, T; Zhang, G | 1 |
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
4 other study(ies) available for erlotinib hydrochloride and staurosporine
| Article | Year |
|---|---|
Randomized clinical trials with biomarkers: design issues.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine | 2010 |
Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Topics: Acrylamides; Amino Acid Substitution; Animals; Area Under Curve; Base Sequence; Carbazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; RNA Interference; Staurosporine; Xenograft Model Antitumor Assays | 2013 |
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
Topics: Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Furans; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Quinazolines; Staurosporine | 2013 |
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |